Physician profile
Walter Tate
NPI 1407681356
$1,058.12
in general payments reported to CMS, 2019-2025
16 companies · $943 in 2025
The $943 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $115 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $262.03 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $217.59 | 2024-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $134.74 | 2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.07 | 2025 | Jardiance |
| Pfizer INC. | $71.86 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.35 | 2025 | |
| Paratek Pharmaceuticals, INC. | $39.11 | 2025 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $33.59 | 2024-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.46 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $21.86 | 2025 | Capvaxive |
| Xeris Pharmaceuticals, INC. | $18.86 | 2025 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $17.12 | 2025 | Auvelity |
| Antares Pharma, INC. | $16.52 | 2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $16.27 | 2024 | Trintellix |
| Abbvie INC. | $15.55 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $11.14 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.